Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Novo Nordisk B : In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/13/2012 | 10:15am CET
News In Kenya, Novo Nordisk tests a new business model to improve access to insulin (13 April 2012)

As part of an official Danish state visit to Kenya, Novo Nordisk on 12 April officially launched a programme to make insulin and diabetes care more accessible to poor populations.

In Kenya, 250,000 people are in need of insulin out of which 80,000 are people with an annual income between 1,500-3,000 US dollars. To make insulin more affordable and accessible to this group, Novo Nordisk has in partnership with local organisations and faith-based hospitals and clinics developed a new business model that includes a streamlined supply chain and treatment centres that are closer to the patients' homes.

The project has reduced price mark-ups in the supply chain to the extent that the insulin can be obtained at 20 cents daily, which is equivalent to a third of the previous price on the private market.

The Kenyan project is the first of three pilots to be launched by Novo Nordisk this year. A second one is about to be launched in India, and a third pilot will be launched in Nigeria later in 2012.

The pilot projects will create valuable learnings on how access to insulin and proper diabetes care can be improved for people with diabetes with very low incomes.

Worldwide, there is a population of 46 million people with diabetes who earn between 4 and 10 dollars per day. In 2030, this group is expected to grow to more than 73 million people.

Diabetes in Africa

According to the International Diabetes Federation, the growth of diabetes in Africa is currently the highest in the world. Close to 15 million people in sub-Saharan Africa currently have diabetes, and this number is expected to rise to around 28 million in 2030. It is estimated that 78% of people with diabetes today are undiagnosed.

In Kenya, the International Diabetes Federation estimates that there are currently around one million people with diabetes in Kenya with urban prevalence up to 10%.

Video from Kenya will be available here Monday.

Contacts details:

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on NOVO NORDISK A/S
02/20 NOVO NORDISK A/S : - Share repurchase programme
02/18 NOVO NORDISK SHAREHOLDER ALERT BY FO : Kahn Swick & Foti, LLC Reminds Investors ..
02/18 NOVO NORDISK A/S : Pomerantz Law Firm Reminds Shareholders with Losses on their ..
02/17 Levi & Korsinsky, LLP Reminds Shareholders of Novo Nordisk A/S of a Class Act..
02/16 NOVO NORDISK A/S : Studies from Novo Nordisk in the Area of Obesity Reported (Ca..
02/16 NOVO NORDISK A/S : Researchers from Novo Nordisk Report Details of New Studies a..
02/16 NOVO NORDISK A/S : Findings in the Area of Proinsulin Reported from Novo Nordisk..
02/16 NOVO NORDISK A/S : Patent Issued for Method for Producing Acylated Peptides (USP..
02/16 NOVO NORDISK A/S : SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Remind..
02/15 NOVO NORDISK A/S : Share repurchase programme
More news
Sector news : Pharmaceuticals - NEC
02:05aDJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- 2nd Upd..
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21 Collapse of Kraft-Unilever tie-up extends run of failed mega-deals
02/21DJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- Update
02/21DJBRISTOL MYERS SQUIBB : Carl Icahn Takes Stake in Bristol-Myers Squibb -- Sources
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/21 A Time To Buy Novo Nordisk
02/13 IBB : Merck Joins The Drug Pricing Coalition For Transparency
02/13 What Growth Rate Is Implied By The Current Price Of Novo Nordisk?
02/13 Novo Nordisk - From Growth To Value?
02/11 National Research Leads 'Safe' Dividend Healthcare Dogs By Yield, Aceto Leads..
Advertisement
Financials ( DKK)
Sales 2017 116 577 M
EBIT 2017 50 067 M
Net income 2017 38 357 M
Finance 2017 14 922 M
Yield 2017 3,08%
P/E ratio 2017 16,08
P/E ratio 2018 14,57
EV / Sales 2017 4,18x
EV / Sales 2018 3,99x
Capitalization 502 537 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 32
Average target price 273  DKK
Spread / Average Target 9,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Mads Krogsgaard Chief Science Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-3.02%70 520
JOHNSON & JOHNSON3.86%323 362
ROCHE HOLDING LTD.4.90%209 882
PFIZER INC.3.51%204 018
NOVARTIS AG3.51%200 997
MERCK & CO., INC.11.23%180 289
More Results